Semaglutide vs Retatrutide

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicSemaglutideRetatrutide
What it is

A GLP-1 receptor agonist. The Wegovy label describes semaglutide as a GLP-1 analogue with 94% sequence similarity to human GLP-1.1

An investigational agonist of the GIP, GLP-1 and glucagon receptors, developed by Eli Lilly and also known as LY3437943.5,8

FDA status

FDA-approved

FDA-approved as Ozempic, Rybelsus and Wegovy1,2,3,4

FDA-approved. Drugs@FDA lists Ozempic (first approved December 5, 2017), Rybelsus (September 20, 2019) and Wegovy (June 4, 2021). The Wegovy label carries a boxed warning about thyroid C-cell tumors seen in rodents.1,2,3,4

Is semaglutide FDA-approved?

In clinical trials

In clinical trials; not FDA-approved5,6,7

Not FDA-approved. FDA states that retatrutide is not a component of an FDA-approved drug and cannot be used in compounding under federal law.7

Is retatrutide FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.9

Not among the six peptides the policy lists.9

FDA compounding safety-risk page

Not addressed in this profile’s sources.

Not addressed in this profile’s sources.

Kinds of studies cited

Large randomized human trials

  • Large randomized human trial A double-blind, placebo-controlled cardiovascular trial (NCT03574597) that randomized 17,604 adults aged 45 or older with established cardiovascular disease and obesity or overweight, without diabetes. The label reports a hazard ratio of 0.80 for major adverse cardiovascular events.1
  • Large randomized human trial A 68-week randomized, double-blind, placebo-controlled weight trial (NCT03548935) in 1,961 adults with obesity, or overweight with a weight-related condition, that excluded type 2 diabetes. It is one of several weight trials the label describes.1
  • Large randomized human trial A randomized, double-blind, placebo-controlled MASH trial (NCT04822181) whose week-72 analysis included 800 adults with moderate to advanced liver fibrosis.1

Large randomized human trials

  • Large randomized human trial A 48-week double-blind, randomized, placebo-controlled Phase 2 trial in 338 adults with obesity, or overweight with a weight-related condition, published in The New England Journal of Medicine.10
  • Controlled human trial A randomized, double-blind Phase 2 trial with placebo and active comparator groups in 281 adults with type 2 diabetes at 42 U.S. centers, published in The Lancet.11
  • Large randomized human trial TRANSCEND-T2D-1, a 40-week double-blind, randomized, placebo-controlled Phase 3 trial in 537 adults with type 2 diabetes, published in The Lancet.8
  • Registered trial without results Phase 3 trials in obesity with cardiovascular disease (NCT05882045) and in obesity with type 2 diabetes or sleep apnea (NCT05929079), listed as completed in registry records updated July 30, 2026. Their results are not part of the sources cited here.12,13
  • Registered trial without results A Phase 3 trial in people with cardiovascular or chronic kidney disease (NCT06383390), listed as active, not recruiting in its August 24, 2026 registry record.14
Records collected

140 ClinicalTrials.gov records and 108 PubMed records collected

8 ClinicalTrials.gov records and 17 PubMed records collected

Area of study

Metabolic and weight, Heart and blood vessels, Liver1

Metabolic and weight5

Latest dated events
  1. FDA’s page on unapproved GLP-1 drugs is updated, as shown by its content-current date.7
  2. DailyMed publishes the Wegovy label version cited on this page.1
  3. FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list.15
  1. FDA’s page on unapproved GLP-1 drugs, which says retatrutide cannot be used in compounding, is updated, as shown by its content-current date.7
  2. Results of TRANSCEND-T2D-1, a Phase 3 trial in type 2 diabetes, are published in The Lancet.8
  3. Results of two Phase 2 trials, in obesity and in type 2 diabetes, are published.10,11

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    WEGOVY (semaglutide) injection and tablet · SPL version 19 · published 2026-06-30 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  2. 2
    Drugs@FDA application NDA209637 · original submission status AP · 2017-12-05 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  3. 3
    Drugs@FDA application NDA213051 · original submission status AP · 2019-09-20 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  4. 4
    Drugs@FDA application NDA215256 · original submission status AP · 2021-06-04 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  5. 5
    Retatrutide in Participants With Type 2 Diabetes and Renal Impairment · record history version 25 · last update posted 2026-07-20 ↗

    ClinicalTrials.gov · Official source · Source checked July 22, 2026

  6. 6
    ClinicalTrials.gov record NCT06297603 · retained source version 2026-11-13:c86dcf0120caf546c9c9fa9df1808025579fcf0e33236ed212dc3df861690ab7 ↗

    ClinicalTrials.gov · Official source · Source checked November 14, 2026

  7. 7
    FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  8. 8
    Efficacy and safety of retatrutide in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial (2026) · PMID 42250575 ↗

    The Lancet · Official source · Source checked November 14, 2026

  9. 9
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  10. 10
    Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial (2023) · PMID 37366315 ↗

    The New England Journal of Medicine · Official source · Source checked November 14, 2026

  11. 11
    Retatrutide for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA (2023) · PMID 37385280 ↗

    The Lancet · Official source · Source checked November 14, 2026

  12. 12
    ClinicalTrials.gov record NCT05882045 · retained source version 2026-07-30:d21e38ddcccc7ab66ec1bddaa910bf3c7a7a3149a43f4ac27918a9e80f8452da ↗

    ClinicalTrials.gov · Official source · Source checked August 14, 2026

  13. 13
    ClinicalTrials.gov record NCT05929079 · retained source version 2026-07-30:d0cad2c0ebfa7ce1f2af088a52c397680123509e21999e7837a0b2b517e9ef04 ↗

    ClinicalTrials.gov · Official source · Source checked August 14, 2026

  14. 14
    ClinicalTrials.gov record NCT06383390 · retained source version 2026-08-24:4bb37a90f79acd41fc8e0a5c8b4745c3c9610a0993eab8f502e836929a21c5ff ↗

    ClinicalTrials.gov · Official source · Source checked September 9, 2026

  15. 15
    FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list ↗

    U.S. Food and Drug Administration · Official source · Source checked July 29, 2026